Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.
about
Targeted therapies in sarcomas: challenging the challengeAssociation of insulin receptor substrate 1 with simian virus 40 large T antigenIL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcomaThe insulin-like growth factor system in cancerEvasion mechanisms to Igf1r inhibition in rhabdomyosarcomaDevelopment of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics.Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells.Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation.Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogeneThe contradictions of the insulin-like growth factor 1 receptor.FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationInsulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-cateninGrowth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suraminCoordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein.Insulin-like growth factor I receptor signaling in transformation by src oncogenes.Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.Susceptibility to apoptosis in insulin-like growth factor-I receptor-deficient brown adipocytes.Molecular and cellular biology of rhabdomyosarcoma.The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251.Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells.Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol.Synthetic peptide sequence from the C-terminus of the insulin-like growth factor-I receptor that induces apoptosis and inhibition of tumor growth.Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway.Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling.Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells.
P2860
Q21285014-9EA312D9-8067-491C-A28C-0C86873FB9A9Q24307564-1A8211B4-A555-4406-A541-A399BF083E45Q24601302-B55CB1A0-FF83-4810-AB28-B6B773CFE229Q27013945-B2EB0FAA-BB07-49A7-8B6C-99B47C622DF8Q30411769-5921F6A0-461E-467F-80BE-3EE2500019EDQ30812778-437B7AA8-40A3-4FD7-B34E-20B3698C98D0Q33248446-9F36D77F-C78D-4ABA-AD1E-C8A855C5E9D4Q33780757-0690B26A-3444-409B-99AD-94C012C3E62DQ33918953-CFD4C717-1D29-42D6-A886-CBD47BD13253Q33959860-AEF927A7-C2AE-45B8-8005-CFBBB738280DQ33964561-3ABFA097-27C6-45F6-A1A1-FB91AF6788C5Q34103628-FB99A231-F442-4DCC-AE36-5B2EFEB9C8DBQ34191937-A8CDD993-3C46-439C-88AE-77F51D878824Q34387886-1E7CF1E6-B59A-4699-B783-98B1F45B85A9Q34928974-CCD8BD08-3BD6-4F58-AF37-5A065D309A18Q35382945-B5CACF05-A90B-4ABB-9AFE-C4AB58F0802CQ35551142-2EF146E6-7148-4B81-B867-424589D32BCEQ35740165-8CE1893F-A176-4D11-BBD5-5EEBB2ED4EE1Q36081413-329639D1-E813-4741-BBB4-66AE27F719C8Q36403135-BBF8626A-FDF5-46A0-BD14-282CA1161119Q36569121-D767F767-A2E1-43AB-B557-6A3272F299DCQ37165350-335C31EC-25ED-4175-B9FD-C76A0F7151B1Q37595492-BBF0E49D-9D5C-4078-A5BB-3ABC9A88B6C4Q37630588-878C6135-C17D-407B-B5F6-5CD5BB8A5B24Q37718282-AB2D062A-3722-4666-BE46-0554DB12F9A2Q37831148-1E8CD3FB-7336-4F84-8EF2-7675F7BA06B5Q38105879-E1159BF4-C611-4C19-88E1-96B724C14C32Q38612221-A343F96B-C65A-498A-BF70-E06B8FE594BAQ39767891-2C90301C-50A6-42B7-BEF4-B88DFB480FF1Q39769976-D062C9E3-1FA8-4A40-9724-CF96C683CE3AQ39817075-D89D0219-95D9-4BEE-8DAE-44FCFF61724DQ40040866-E3994213-DCFC-4891-BAEE-189280CF111BQ40277182-DB02D34B-B6DE-425E-8530-67C4D059D5AEQ40590032-F7C2125A-6CC3-4137-B3C3-BEA4B6DF98CEQ40616867-85C35C7B-86F6-45A7-AA43-1CC8F4B4DCECQ40817283-E666DEEA-6E05-4A35-8C8C-6C111244E95BQ40933956-7EDBA69C-4E95-41C4-9B9F-353D81466CE6Q40952840-3A149075-5AA6-4A25-A951-61DAC477B591Q40972597-1FEFB56B-ABB9-4093-A3FD-35CB6F49FE7FQ41021450-B42293AA-41F2-431D-B8D9-0E2C34E27540
P2860
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@ast
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@en
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@nl
type
label
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@ast
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@en
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@nl
prefLabel
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@ast
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@en
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@nl
P2093
P2860
P356
P1476
Antisense-mediated reduction i ...... man alveolar rhabdomyosarcoma.
@en
P2093
D N Shapiro
L H Shapiro
P J Houghton
P2860
P304
P356
10.1172/JCI117441
P407
P577
1994-09-01T00:00:00Z